Cargando…

Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib

Sorafenib, an oral multikinase inhibitor, exhibits a highly variable absorption profile due to enterohepatic reabsorption and poor solubility. SYO-1644 improved the solubility of sorafenib by nanoparticulation technology leading to enhanced bioavailability. To evaluate the pharmacokinetically equiva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huh, Ki-Young, Hwang, Se-jung, Park, Sang-Yeob, Lim, Hye-Jung, Jin, Mir-yung, Oh, Jae-seong, Yu, Kyung-Sang, Chung, Jae-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145937/ https://www.ncbi.nlm.nih.gov/pubmed/33925058 http://dx.doi.org/10.3390/pharmaceutics13050629

Ejemplares similares

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
por: Karbownik, Agnieszka, et al.
Publicado: (2020)

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2020)

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
por: Pécuchet, N, et al.
Publicado: (2012)

Preclinical Pharmacokinetic Interaction and Histopathological Analyses of Hedyotis diffusa on Sorafenib in Rats
por: Ting, Chin-Tsung, et al.
Publicado: (2021)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Pharmacokinetic Drug Interaction Study of Sorafenib and Morphine in Rats
por: Karbownik, Agnieszka, et al.
Publicado: (2021)

Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
por: Cui, Yanjun, et al.
Publicado: (2022)

Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study
por: Panetta, John C., et al.
Publicado: (2021)

Potential Therapeutic Agents against Paclitaxel—And Sorafenib-Resistant Papillary Thyroid Carcinoma
por: Kim, Seok-Mo, et al.
Publicado: (2022)

Necrotizing fasciitis associated with sorafenib treatment
por: Kang, Ho Won, et al.
Publicado: (2019)

The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism
por: Wang, Xianming, et al.
Publicado: (2017)

Sorafenib Induces Delayed-Onset Cutaneous Hypersensitivity: A Case Series
por: Sohn, Kyoung-hee, et al.
Publicado: (2015)

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
por: Kim, Soo Young, et al.
Publicado: (2018)

Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
por: Mir, Olivier, et al.
Publicado: (2012)

Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats
por: Ting, Chin-Tsung, et al.
Publicado: (2017)

Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular Carcinoma
por: Cha, Jihye, et al.
Publicado: (2013)

Impact of Crystal Habit on the Dissolution Rate and In Vivo Pharmacokinetics of Sorafenib Tosylate
por: Phan, Chi Uyen, et al.
Publicado: (2021)

Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors
por: Cawley, Jacob R., et al.
Publicado: (2022)

Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review
por: Kim, Tae Suk, et al.
Publicado: (2017)

Pancreatic Endocrine Tumors: A Report on a Patient Treated with Sorafenib
por: Jeong, Hee Kyoung, et al.
Publicado: (2011)

Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib
por: Kang, Dongxu, et al.
Publicado: (2017)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Practical Effect of Sorafenib Monotherapy on Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis
por: Jeong, Soung Won, et al.
Publicado: (2013)

Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
por: Kang, Seong Hee, et al.
Publicado: (2018)

Recurrent Hypoglycemia Triggered by Sorafenib Therapy in a Patient with Hemangiopericytoma
por: Lee, Si Won, et al.
Publicado: (2014)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy
por: Jo, Yunhui, et al.
Publicado: (2018)

Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data
por: Kim, Do Young, et al.
Publicado: (2016)

Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation
por: Lee, Taehyang, et al.
Publicado: (2018)

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort
por: Trédan, Olivier, et al.
Publicado: (2023)

Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma
por: Ha, Yeonjung, et al.
Publicado: (2016)

Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma
por: Seo, Sang Hyun, et al.
Publicado: (2023)

Nanoparticulated docetaxel exerts enhanced anticancer efficacy and overcomes existing limitations of traditional drugs
por: Choi, Jinhyang, et al.
Publicado: (2015)

Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib
por: Eun, Jung Woo, et al.
Publicado: (2023)

Effectiveness of Sorafenib in Hepatic Hemangioma
por: Tiwari, Prateek, et al.
Publicado: (2017)

Sorafenib as an Inhibitor of RUVBL2
por: Nano, Nardin, et al.
Publicado: (2020)

Sorafenib in Dupuytren and Ledderhose Disease
por: Schoenfeld, Joshua D, et al.
Publicado: (2022)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

The Influence of Paracetamol on the Penetration of Sorafenib and Sorafenib N-Oxide Through the Blood–Brain Barrier in Rats
por: Karbownik, Agnieszka, et al.
Publicado: (2020)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_110trq19nksfl9k17s2r3rogqd